CV Rizos, M Elisaf, DP Mikhailidis, EN … - Expert Opin. Drug …, 2009 - informahealthcare.com Background: Thiazolidinediones (TZDs) are widely used antidiabetic drugs with proven efficacy
regarding mainly surrogate markers of diabetes management. However, efficacy on surrogate
markers may not always translate into benefits in clinical outcomes. Thiazolidinediones ... Cited by 5 - Related articles - All 5 versions
Z Bloomgarden, Y Handelsman - Journal of Diabetes, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Related articles
GF Davies, AR Ross, TG Arnason, BHJ Juurlink, TAA … - Cancer Letters, 2009 - Elsevier We previously demonstrated that the PPARγ agonist Troglitazone (TRG), a potent antiproliferative
agent, in combination with the anthracycline antibiotic Doxorubicin (DOX), is an effective killer
of multiple drug resistant (MDR) human cancer cells. Cell killing was accompanied by ... Related articles - All 2 versions
M Monami, C Lamanna, D Balzi, N Marchionni, E … - Acta Diabetologica - Springer Abstract This study was aimed at the assessment of incidence of malignancies in type 2 diabetic
patients trea- ted with different sulphonylureas. A matched case–control study was
performed. Cases were 195 diabetic patients aged 69.0 ± 9.2 years who had an incident ... Related articles - All 2 versions
C Jennifer… - PPAR research, 2009 - hindawi.com Breast cancer is the most prominent cancer among females in the United States. There are a
number of risk factors associated with development of breast cancer, including consumption
of a high-fat diet and obesity. Plasminogen activator inhibitor-1 (PAI-1) is a cytokine ... Related articles - Cached - All 15 versions